Literature DB >> 11455260

Fibrinolytic preflush upon liver retrieval from non-heart beating donors to enhance postpreservation viability and energetic recovery upon reperfusion.

T Minor1, A Hachenberg, R Tolba, D Pauleit, S Akbar.   

Abstract

BACKGROUND: Our objective was to evaluate graft equilibration with high viscosity (University of Wisconsin solution [UW]) or low viscosity (Bretschneider's histidine-tryptophan-ketoglutarate [HTK]) during liver procurement from non-heart beating donors (NHBD) and the potential impact of a preceding fibrinolysis with streptokinase on postpreservation viability.
METHODS: After 60 min of cardiac arrest, rat livers were perfused by gravity (60 cm H2O) via the portal vein with either 60 ml of HTK, 20 ml of UW, or 20 ml of Ringer's solution (22 degrees C including 7500U of streptokinase) and, subsequently, 20 ml of UW. After 24 h of storage at 4 degrees C, viability of the livers was assessed upon isolated reperfusion in vitro.
RESULTS: Magnetic resonance imaging revealed severe perfusion deficits, which were mildly attenuated with HTK, upon flush-out with UW. After preflush with streptokinase, a mostly homogenous distribution of the preservation solution was observed throughout the liver tissue. The choice of the flush-out solution (UW or HTK) had no influence on parenchymal enzyme leakage, hepatic bile production, or tissue levels of ATP after reperfusion of the livers. Fibrinolytic preflush, however, resulted in a relevant and significant improvement of structural integrity as well as functional and metabolic recovery.
CONCLUSIONS: Compromised vascular tissue perfusion upon organ harvest in NHBD triggers graft dysfunction after cold storage and can easily be circumvented by temporary fibrinolysis before graft retrieval.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11455260     DOI: 10.1097/00007890-200106270-00015

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Current status and recent advances of liver transplantation from donation after cardiac death.

Authors:  M Thamara Pr Perera; Simon R Bramhall
Journal:  World J Gastrointest Surg       Date:  2011-11-27

Review 2.  Strategies to optimize the use of marginal donors in liver transplantation.

Authors:  Daniele Pezzati; Davide Ghinolfi; Paolo De Simone; Emanuele Balzano; Franco Filipponi
Journal:  World J Hepatol       Date:  2015-11-18

3.  Optimising post-conditioning time of marginal donor livers.

Authors:  Steffen Manekeller; Alexandra Seinsche; Judith Stegemann; Andreas Hirner
Journal:  Langenbecks Arch Surg       Date:  2008-02-19       Impact factor: 3.445

4.  Novel short-term hypothermic oxygenated perfusion (HOPE) system prevents injury in rat liver graft from non-heart beating donor.

Authors:  Philipp Dutkowski; Katarzyna Furrer; Yinghua Tian; Rolf Graf; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

5.  Ultrastructural changes in porcine liver sinusoidal endothelial cells of machine perfused liver donated after cardiac death.

Authors:  Hiroki Bochimoto; Yo Ishihara; Nur Khatijah Mohd Zin; Hiroyoshi Iwata; Daisuke Kondoh; Hiromichi Obara; Naoto Matsuno
Journal:  World J Gastroenterol       Date:  2022-05-21       Impact factor: 5.374

6.  Donation after cardio-circulatory death liver transplantation.

Authors:  Hieu Le Dinh; Arnaud de Roover; Abdour Kaba; Séverine Lauwick; Jean Joris; Jean Delwaide; Pierre Honoré; Michel Meurisse; Olivier Detry
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

Review 7.  Systematic Review and Meta-Analysis on the Impact of Thrombolytic Therapy in Liver Transplantation Following Donation after Circulatory Death.

Authors:  Kumar Jayant; Isabella Reccia; Francesco Virdis; A M James Shapiro
Journal:  J Clin Med       Date:  2018-11-08       Impact factor: 4.241

8.  A Dual Protective Effect of Intestinal Remote Ischemic Conditioning in a Rat Model of Total Hepatic Ischemia.

Authors:  Zoltan Czigany; Koichiro Hata; Wei Lai; Timo Schwandt; Yuzo Yamamoto; Shinji Uemoto; Rene H Tolba
Journal:  J Clin Med       Date:  2019-09-26       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.